Inmed Pharmaceuticals Inc (IMLFF) 0.0750 $IMLFF InMed

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Inmed Pharmaceuticals Inc (IMLFF) 0.0750 $IMLFF

InMed Announces Appointment of Eric A. Adams as CEO, President and Director
Marketwire Canada - Thu Jun 16, 8:03AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Global Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/s368wq/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Obstructive Pulmonary Disease (COPD) Overview - Therapeutics Development - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Overview - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AlgiPharma AS - C4X Discovery Limited - Carolus Therapeutics, Inc. - Cellular Biomedicine Group, Inc. - Chiesi Farmaceutici SpA - Circassia Pharmaceuticals Plc - Hydra Biosciences, Inc. - iCeutica, Inc. - InMed Pharmaceuticals Inc. - Innate Pharma SA - Invion Limited - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Nostrum Pharmaceuticals, LLC - Novabiotics Limited - Novartis AG - OPKO Health, Inc. - Quark Pharmaceuticals, Inc. - Re-Pharm Limited - Recipharm AB - Respira Therapeutics, Inc. - Respiratorius AB - rEVO Biologics, Inc. - Seoul Pharma Co., Ltd. - SkyePharma Plc - Spring Bank Pharmaceuticals, Inc. - Stelic Institute & Co. - sterna biologicals Gmbh & Co KG - Sucampo Pharmaceuticals, Inc. - Sunovion Pharmaceuticals Inc. - Synovo GmbH - Syntrix Biosystems, Inc. - Yuhan Corporation - Yungjin Pharm. Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/s368wq/chronic
JNJ: 119.92 (-0.80), OPK: 9.83 (-0.03), SCMP: 11.31 (-0.11), RBIO: (), CBMG: 14.07 (-0.21), NVS: 81.34 (-0.60)

Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.23 (-0.02), AGN: 253.14 (+0.21), ACAD: 33.64 (+0.37), ITEK: 6.84 (-0.05), GILD: 81.00 (+0.41), GKOS: 30.35 (-1.29), AERI: 19.15 (+0.08), CLBS: 5.45 (-0.02)

InMed Strengthens Board With Appointment of Experienced Biotech Executive Adam Cutler
Marketwired - Mon Nov 23, 5:01AM CST
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems is pleased to announce the appointment of Adam Cutler to the Board of Directors.

InMed Pharmaceuticals Inc. Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Fri Nov 06, 12:45PM CST
full story)

InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
Marketwired - Wed Nov 04, 4:01AM CST
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.

InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.

InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).

InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
ABUS: 3.74 (+0.02), TKMR: 10.83 (+0.58)

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling.

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS.

Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 1.02 (-0.01), SHPG: 199.82 (+1.22), GSK: 44.16 (-0.33)

Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 199.82 (+1.22), GSK: 44.16 (-0.33)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Into Guess?, Inc.: Are Fiduciary Duties at Risk?

Updated Category News Views 121

Introduction to the Investigation Recently, a significant issue has arisen concerning Guess?, Inc. (NYSE: GES) and its handling of a pending merger with Authentic Brands Group LLC. This acquisition deal, valued at $16.75 per share, has prompted a legal investigation to determine whether the company's board of directors and top executives may have breached their fiduciary...

Continue Reading
Count Down to Class Action: Important News for GO Investors

Updated Category News Views 281

Important Deadline for Grocery Outlet Holding Corp. Investors As the deadline for the class action lawsuit approaches for Grocery Outlet Holding Corp. (NASDAQ: GO), investors are urged to pay close attention. The law firm Kessler Topaz Meltzer & Check, LLP has announced that investors who purchased or acquired Grocery Outlet securities from November 7, 2023, to May 7,...

Continue Reading
Discover KLIMB Jr.: The Latest in Pet Training Innovation

Updated Category News Views 239

Introducing the KLIMB Jr. by Blue-9 Pet Products Blue-9 Pet Products has made a remarkable stride in pet care with the introduction of the KLIMB Jr., a compact and versatile training platform for dogs and cats. This innovative product serves as a perfect tool for pet owners aiming to enhance their pets’ training and daily enrichment activities. A Tailored Solution for...

Continue Reading
Elsevier, Lancet Awards Highlight Community Health Impact

Updated Category News Views 62

Pioneering Health Awards Make Waves Amidst our swirling universe of breakthroughs and challenges, three research teams just snagged the spotlight. Recognized by the Elsevier Foundation and The Lancet in their first-ever Evidence to Impact Awards. These folks aren't just scribbling in labs—they're rolling up their sleeves and getting those much-needed health solutions...

Continue Reading
k-ID's Kai SDK: Age-Adaptive Design Revolution

Updated Category News Views 139

New Horizons for Developers Today, if you're building an app, you're just as likely to be wrangling with legal regulations as you are writing code. That's where k-ID’s new SDK, Kai, comes into play—it's not just another tool in the shed, it’s the whole toolbox for dealing with age-specific app requirements everywhere. The Changing App Landscape Why does this matter?...

Continue Reading